SFM
BMRN icon

Sphera Funds Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sphera Funds Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-80,000
Closed -$7.4M – 110
2016
Q3 		$7.4M Buy
+80,000
New +$7.53M 1.21% 18
2015
Q3 		– Sell
-1,000
Closed -$13.7M – 129
2015
Q2 		$13.7M Buy
+1,000
New +$124K 1.34% 13

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's BMRN Position: Q1 2026 in Review

Sphera Funds Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 4.8% in Q1 2026, selling an estimated $414K and leaving 139,900 shares worth $7.9M. The position accounts for 1.26% of the portfolio, ranked #21.

Sphera Funds Management first reported a position in BMRN in Q2 2014 and has held it in 19 quarters since. The position peaked at $21.3M in Q4 2019. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Sphera Funds Management held 139,900 shares of BioMarin Pharmaceuticals worth $7.9M as of Q1 2026.
  • Sphera Funds Management sold 7,100 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $414K.
  • BioMarin Pharmaceuticals made up 1.26% of Sphera Funds Management's portfolio in Q1 2026, its #21 holding.
  • Sphera Funds Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 19 quarters since.
  • Sphera Funds Management's BioMarin Pharmaceuticals position peaked at $21.3M in Q4 2019.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.